Due to health issues, this site is no longer maintained and will be shut down shortly. |
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine.
$1.25 +0.06 (5.04%)
As of 03/24/2023 16:00:01 EST IEX book CBOE book
2022 © Stock Market MBA, Inc.